Peptides studied for blood-vessel growth and mitochondrial capacity relevant to heart health and endurance
Cardiovascular capacity depends on two things: blood vessels that carry oxygen to working tissue, and the mitochondria inside cells that burn that oxygen for energy. The compounds here are linked to those processes in different ways — some to blood-vessel growth and the nitric-oxide pathway, others to the energy machinery inside cells. Most of the evidence is from animals and laboratory work; human data specific to heart health and endurance is limited, and in one case (SS-31) human heart-failure trials have failed.
1The biology of this goal
To improve endurance, the body needs to deliver more oxygen to muscles and use it more efficiently. Oxygen travels through blood vessels, so growing new vessels and widening existing ones helps carry more of it. Nitric oxide is a signal the body makes to relax and widen blood vessels. Once oxygen reaches a cell, tiny structures called mitochondria — the cell's power plants — turn it into usable energy. When mitochondria are damaged or stressed, they produce less energy and release harmful byproducts, so protecting them matters for stamina and for the heart, which never stops working.
Human trials report only that intravenous BPC-157 was well tolerated with no measurable effect on cardiac biomarkers; the angiogenic and nitric-oxide mechanisms are described in reviews of largely preclinical data, and community and practitioner commentary describe possible endurance benefit.
BPC-157 is a synthetic 15-amino-acid peptide first isolated from human gastric juice. It is relevant to heart health and endurance because studies link it to the growth of new blood vessels and to the nitric-oxide pathway that widens vessels. A small human safety study infused it intravenously and found no measurable effect on heart biomarkers.
Intravenous infusion of 10 mg BPC-157 in 250 cc normal saline over one hour produced no measurable effects on biomarkers of the heart, liver, kidneys, thyroid, or blood glucose.1
Intravenous infusion of 20 mg BPC-157 in 250 cc normal saline over one hour likewise produced no measurable effects on those biomarkers.1
BPC-157 activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis.2
BPC-157 promotes angiogenesis, fibroblast activity, and neuromuscular stabilization.2
Practitioner commentary describes very early in vivo pharmacokinetic research suggesting BPC-157 may optimize endurance training, metabolism, recovery, and tissue repair.3
What this doesn't establish
No human study shows that BPC-157 grows blood vessels, raises endurance, or improves cardiovascular capacity — the only human data is a two-person safety pilot with no efficacy endpoints.
Animal and laboratory studies suggest TB-4 and its derivative TB-500 promote angiogenesis and tissue repair, with additional cardiac and developmental findings in rodent models.
TB-500 is a lab-made version of thymosin beta-4, a small peptide found in nearly every human cell. It is relevant to heart health because it is linked to the growth of new blood vessels. In animal studies it is also reported to be present in and to support the developing heart.
TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models.6
TB4 is involved in angiogenesis, cell survival, cell migration, and fetal development.4
Maternal TB4 treatment in mice was associated with more advanced development of lungs, heart, kidney, cerebral cortex, and notochord at histology.4
Human cardiovascular or endurance data are lacking, and sources note human orthopaedic evidence is absent; sources also disagree on whether the vendor fragment matches the full-length protein used in most research.
Human observational work (tier 1) links humanin levels to aging and cardiovascular disease, while animal and laboratory studies suggest it protects cells and suppresses cell death in cardiovascular and metabolic disease models; no human trials of administering humanin as a drug have been published.
Humanin is a small peptide encoded inside the mitochondria — the cell's power plants — and acts as a stress signal sent to the rest of the body. It is relevant to heart health because it is reported to protect cells, including heart cells, from damage, and its natural levels fall with age. Its role in mitochondrial function is why it is discussed for cardiovascular and metabolic health.
Alterations of humanin levels are associated with general aging and could influence the development of age-related chronic metabolic, cardiovascular, and neurological diseases.7
A compensatory increase in humanin synthesis and secretion could preserve mitochondrial function and overall cellular vitality.7
Excessive humanin concentrations can have deleterious consequences and are associated with conditions such as cancer and heart failure.7
Humanin protects cells against diseases including diabetes mellitus, cardiovascular, and neurodegenerative diseases, significantly suppressing apoptosis in in vitro and in vivo studies.8
Humanin has shown beneficial effects in diverse disease models including stroke, cardiovascular disease, and cancer.9
What this doesn't establish
No study shows that giving humanin improves human heart function, endurance, or cardiovascular capacity, and its cardiovascular associations are correlational — high levels are also linked to heart failure.
Animal and laboratory studies suggest MOTS-c mimics aerobic exercise and protects heart and metabolic tissue, and one mechanistic source (tier 1) classes it among cytoprotective mitochondrial-derived peptides; direct human cardiovascular or endurance trials are not reported here.
MOTS-c is a small 16-amino-acid peptide encoded inside mitochondrial DNA, discovered in 2015. It is relevant to endurance because it switches on AMPK, a cellular fuel sensor, and reproduces several effects of exercise in animals — so much so that sources call it an 'exercise-mimetic.' It is found in the heart and many other tissues.
MOTS-c is a mitochondrial-derived peptide that plays a cytoprotective role by helping preserve mitochondrial function and cell viability under stressful conditions.11
MOTS-c is widely distributed across tissues including the heart in rodents and humans.10
Intraperitoneal MOTS-c in fed mice significantly reduced blood glucose and visceral fat, with results similar to aerobic exercise.10
MOTS-c can modulate antioxidant defence mechanisms during aerobic exercise to reduce diabetic myocardial damage in rat heart tissue.10
The Keap1-Nrf2 antioxidant pathway is activated by high ROS, aerobic exercise, or MOTS-c in type 2 diabetes models.10
Reviews describe MOTS-c as applicable to aging, cardiovascular disease, insulin resistance, and inflammation.12
What this doesn't establish
The exercise-like and cardioprotective effects are shown in rodents and cells, not in human endurance or heart-health trials, and one source notes mitochondrial-derived peptides can also worsen inflammatory signalling in senescent cells.
Human trials have been conducted (tier 1) but clinical trials in heart failure and primary mitochondrial myopathy have failed, even though preclinical models and dog studies show cardiac benefit such as increased left ventricular ejection fraction.
SS-31 (elamipretide) is a small synthetic peptide that homes in on mitochondria, the cell's power plants. It is relevant to heart health because it protects a special mitochondrial fat called cardiolipin, which keeps the energy-producing machinery organized so cells make more energy and fewer harmful byproducts. It has been studied in heart failure, though human heart-failure trials have not succeeded.
Preclinical studies demonstrated protective and restorative efficacy of elamipretide in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness.13
Elamipretide increased left ventricular ejection fraction in dog models of heart failure with reduced ejection fraction.14
Clinical trials in heart failure and primary mitochondrial myopathy have failed.15
SS-31 is rapidly absorbed after subcutaneous administration and concentrates in the kidney but is also taken up by the heart, liver, skeletal muscle, and lungs.15
What this doesn't establish
Despite strong preclinical cardiac data, the human heart-failure trials did not succeed, and treatments longer than four weeks have not been studied, so durable cardiovascular or endurance benefit in people is not established.
These compounds split into two functional camps for this goal. BPC-157 and TB-500 both drive blood-vessel growth but through entirely different targets — BPC-157 through VEGF/nitric-oxide signalling and TB-500 through actin regulation — so they are discussed as a complementary oxygen-delivery pair rather than a redundant one. On the mitochondrial side, humanin, MOTS-c, and SS-31 all aim at protecting the cell's energy machinery by non-overlapping routes: MOTS-c works upstream through AMPK and Nrf2 antioxidant genes, SS-31 physically stabilizes cardiolipin and the electron-transport supercomplexes, and humanin signals anti-apoptotic survival programs through receptors — making humanin+MOTS-c, humanin+SS-31, and MOTS-c+SS-31 plausibly complementary combinations. BPC-157 and MOTS-c share some cytoprotective and antioxidant signalling and are considered compatible. There is no documented interaction data in our library for BPC-157 with humanin or SS-31, or for TB-500 with humanin, MOTS-c, or SS-31 — that is an absence of evidence, not a clearance.
BPC-157 + TB-500
May be complementary
BPC-157 and TB-500 drive tissue repair through entirely different molecular targets (VEGF/NO signalling vs. actin regulation), so they are frequently discussed as a complementary healing pair rather than a redundant one.
Humanin + MOTS-c
May be complementary
Both humanin and MOTS-c are mitochondrial-derived peptides ('mitokines') that signal cellular stress and improve metabolism, but they work through different downstream routes — humanin is chiefly cytoprotective/anti-apoptotic (Bax inhibition, STAT3, PI3K/Akt) while MOTS-c drives AMPK activation and Nrf2 antioxidant responses. Together they cover complementary arms of the same mitochondrial-stress response, which is why they are often discussed as a metabolic/longevity pairing.
Humanin + SS-31
May be complementary
Both aim to protect mitochondria and reduce oxidative/ischemic injury, but by different means: SS-31 physically stabilizes the inner-membrane cardiolipin and electron-transport supercomplexes to preserve ATP output and cut ROS, whereas humanin signals through receptors to trigger anti-apoptotic and anti-inflammatory programs. One protects mitochondrial machinery directly, the other signals survival — a genuinely complementary combination.
MOTS-c + SS-31
No known conflict in the research
Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.
5 other pairings have no documented interaction in our data — that is not a safety clearance.
BPC-157 + Humanin
BPC-157 + SS-31
Humanin + TB-500
MOTS-c + TB-500
SS-31 + TB-500
4Related but not studied for this goal
These share some of this goal's biology and are not off-target — but their research is elsewhere: on the skin, or on another condition. Listed so you know we saw them.
Epithalon shares mitochondrial function with this goal, but only 3 of its 161 research claims mention improve heart health and endurance; it has not been studied for it.
5Compounds we looked at and left out
These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.
Thymalin is linked to nitric-oxide pathway, but in this compound that activity is about immune system regulation and restoration.
“Sources describe Thymalin as a polypeptide complex isolated from the thymus gland of young calves that acts as an immune regulator.”— from its own profile
Semax is linked to new blood-vessel growth, but in this compound that activity is about stroke recovery and cerebral blood circulation after brain injury.
“After brain injury such as stroke, it appears to dial down inflammation and oxidative stress while turning on genes tied to nerve repair, new blood vessels, and neuron survival.”— from its own profile
Semaglutide is linked to mitochondrial function, but in this compound that activity is about weight loss and blood sugar management.
“Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural gut hormone GLP-1. It tells the pancreas to release more insulin and less glucagon, but only when blood sugar is elevated, which lowers blood glucose with a low risk of hypoglycemia. It also acts on appetite regulation and slows the rate at which the stomach empties, leading to reduced food intake and weight loss.”— from its own profile
Cerebrolysin is linked to mitochondrial function, but in this compound that activity is about neurological protection and brain function (stroke, traumatic brain injury, dementia).
“Researchers propose it protects neurons by reducing cell death, calming inflammation, lowering oxidative stress (free radicals), and supporting blood vessels in the brain.”— from its own profile
Noopept is linked to mitochondrial function, but in this compound that activity is about cognitive enhancement and neuroprotection.
“Animal and cell studies attribute its cognitive and neuroprotective actions to raising the neurotrophic factors BDNF and NGF, boosting acetylcholine signaling, reducing oxidative stress and glutamate excitotoxicity, and increasing HIF-1 activity.”— from its own profile
6What we can't tell you yet
Across all five compounds, direct human evidence for improved endurance or cardiovascular capacity is essentially absent: the strongest human data here is a small BPC-157 safety pilot with no efficacy endpoints, and the SS-31 heart-failure trials that were conducted failed. Nearly all cardiovascular and mitochondrial benefit described is from animal and laboratory models.
Pairings we could not confirm
BPC-157 + MOTS-c: proposed as compatible, but the two compounds' own mechanism data did not support the pairing.
This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.
See something wrong or out of date on this page? Report it.